Silver Book Fact

Potential value of pneumonia vaccine

Use of PCV13 (13-valent pneumococcal conjugate vaccine) in older adults is estimated to have the potential to reduce total healthcare costs by $3.5 billion and total societal costs by $7.4 billion.

Weycker D, Sato R, Strutton D, Edelsberg J, et al. Public Health and Economic Impact of 13-Valent Pneumococcal Conjugate Vaccine in U.S. Adults Aged > 50 Years. Vaccine. 2012; 30(36): 5437-44. http://www.sciencedirect.com/science/article/pii/S0264410X12008286

Reference

Title
Public Health and Economic Impact of 13-Valent Pneumococcal Conjugate Vaccine in U.S. Adults Aged > 50 Years
Publication
Vaccine
Publication Date
2012
Authors
Weycker D, Sato R, Strutton D, Edelsberg J, et al
Volume & Issue
Volume 30, Issue 36
Pages
5437-44
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value
  • Future Value

Related Facts

  • Measles vaccines reduced cases from 6 million to 1 million per year
    Vaccination for measles reduced the number of worldwide deaths from 6 million in 1974 to less than 1 million per year.  
  • Cost effectiveness of MMR vaccine
    For every dollar spent on the MMR (measles, mumps, and rubella) vaccine, $21 is saved.  
  • Annual flu vaccine could save 275,000 QALYs
    Offering the influenza vaccine annually to all people over the age of 50 would save around 275,000 quality-adjusted life years over the lifetimes of a birth cohort of 4 million.…  
  • Staff vaccination in nursing homes reduces mortality rates of residents
    Mortality rates in nursing home residents were 42% lower in facilities with higher staff vaccination coverage compared with control facilities.  
  • Pre-surgery antibiotic use reduces 6-day mortality by 50% in elderly
    Effective pre-surgery antibiotic use can reduce 60-day mortality in the elderly by 50%.